<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131942">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384266</url>
  </required_header>
  <id_info>
    <org_study_id>AEC-001</org_study_id>
    <nct_id>NCT01384266</nct_id>
  </id_info>
  <brief_title>A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery</brief_title>
  <official_title>A Randomized, Multicenter, Masked Evaluation of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate for the Treatment of Inflammation Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associated Eye Care, Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Associated Eye Care, Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are routinely given steroid eye drops following cataract surgery. This study will
      compare 2 approved drops:Loteprednol Etabonate versus Prednisolone Acetate Eye drops used
      following cataract surgery. Patients will be randomly assigned to one drop or the other, and
      evaluated for inflammation and intraocular pressure as part of the comparison. The study
      Doctor will be masked as to which drop the patient receives to avoid bias.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular inflammation grading</measure>
    <time_frame>Day 21 Post-op</time_frame>
    <description>Slit Lamp examination will be done at each visit to grade intraocular inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure spikes</measure>
    <time_frame>Day 21 post-op</time_frame>
    <description>Intraocular pressure(IOP) will be measured at each visit.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Intraocular Inflammation</condition>
  <arm_group>
    <arm_group_label>Subjects undergoing Cataract Surgery</arm_group_label>
    <description>Subjects undergoing routine cataract surgery</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Eye Clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects age 18 and older undergoing routine cataract surgery.

        Exclusion Criteria:

          1. Subjects being treated for elevated intraocular pressure, retinopathy, maculopathy,
             cornea or vitreous opacities that would interfere with visual acuity.

          2. Subjects with diabetes, pseudoexfoliation, uveitis, corneal endothelial disease, or
             active Herpes Simplex Virus(HSV) or Herpes Zoster Virus(HZV) Pupil Stretch and/or
             Limbal Relaxing Incision(LRIs) will be allowed.

          3. Subjects with previous ocular trauma or intraocular surgery

          4. Subjects with sensitivities to steroids.

          5. Women who are not post-menopausal or are of child bearing potential will be excluded.

          6. Intraoperative complications during surgery including posterior capsule rupture and
             vitreous loss

          7. Subjects with best visual potential in the fellow eye worse than 20/60

          8. Subjects who are expected to require concurrent ocular or systemic therapy with
             non-steroidal anti-inflammatory drugs (NSAIDS) mast cell stabilizers, antihistamines,
             or decongestants within 2 days prior to or during the 21 days following surgery.
             (Intraoperative NSAIDS for mydriasis are permitted.) 325 mg Aspirin is permitted.

          9. Subjects who are expected to require concurrent ocular or systemic corticosteroids,
             immunosuppressants (including Restasis) within 14 days prior to or 21 days following
             surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen S Lane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associated Eye Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen S Lane, MD</last_name>
    <phone>651-275-3000</phone>
    <email>sslane@associatedeyecare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward J Holland, MD</last_name>
      <phone>859-331-9000</phone>
      <email>eholland@cincinnatieye.com</email>
    </contact>
    <investigator>
      <last_name>Edward J Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Eye Care</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen S Lane, MD</last_name>
      <phone>651-275-3000</phone>
      <email>sslane@associatedeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Stephen S Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 27, 2011</lastchanged_date>
  <firstreceived_date>January 13, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Stephen S. Lane, MD</name_title>
    <organization>Associated Eye Care</organization>
  </responsible_party>
  <keyword>Intraocular Inflammation following routine Cataract Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polystyrene sulfonic acid</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
